I N N O V A T E
A U S T I N
V O L . 1
Imagine discovering a dangerous new disease with no known cure. Traditional drug development takes years, but a major epidemic is right around the corner. What if you could simply plug some information into a computer and generate a treatment automatically? It may sound like science fiction, but Macromoltek is turning that fantasy into a reality. Macromoltek was founded in 2010 by motherdaughter duo Susana Kaufmann and Dr. Monica Berrondo. With Susana’s prodigious knowledge of business and software development, and Monica’s biotech and molecular modeling experience (including work on the Rosetta biomolecular modeling project), they set out to develop a system to bridge the gap between computational insight and pharmaceutical advancement. Antibody-based drugs play a vital role in the treatment of anything from cancer to autoimmune disease. Because antibodies are highly specific to their targets, they can be used to carefully
98
single out a system of interest without triggering unwanted side effects. Given their applicability to a wide variety of problems, the use of these drugs has expanded wildly since the early 2000s, with over fifty distinct antibody therapies receiving FDA approval in the last decade alone. Macromoltek is a biotech company focused on the use of computational biology to create new antibody therapeutics. Their efforts are powered by proprietary software, cutting edge machine learning techniques, and decades of combined research and experience. This software and experience, in turn, empower their de novo